alexa Abstract | Pioglitazone induced weight changes in type 2 diabetic patients

International Journal of Collaborative Research on Internal Medicine & Public Health
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)


Background: Pioglitazone, a member of the thiazolidinedione drug family, with hypoglycemic action, is widely used for the therapy of type 2 diabetic patients.

Aims and Objectives: The effect of pioglitazone on body weight was investigated and the effects of monotherapy and combinations with other hypoglycemic agents were compared.

Methodology: A prospective study on 379 type 2 diabetic cases, who were being given pioglitazone for the first time, as either monotherapy or in combination with other oral hypoglycemic agents or insulin. Parameters were analyzed by Kruskal-Wallis test, considering p <0.05 as significant.

Results: Pioglitazone therapy resulted in weight gain, especially in females, although triglyceride and lipoprotein levels were not adversely affected. Concomitant use of pioglitazone along with insulin or any of the sulfonylurea group of drugs accounted for more weight gain; (2.57±1.4 kg) and (2.31±1.2 kg) respectively; than that by pioglitazone alone (2.23±1.3 kg). However pioglitazone combination therapy with metformin and alpha glycosidase inhibitors revealed lower weight gain: (0.31±0.2 kg) and (0.16±0.4 kg) respectively. Higher doses of pioglitazone were associated with more important weight gain.

Limitations of the study:

1. The study is an open-label prospective observational study and not a double blinded randomized controlled trial.

2. Long term changes in weight were not assessed, as the mean follow up period was only 6 months.

3. There were very few patients (only 28) on pioglitazone monotherapy.

Conclusions: Pioglitazone increases body weight, although less than other thiazolidinediones. Hence it should not be indiscriminately used in high doses and when used, it should be supplemented with metformin and alpha glycosidase inhibitors.

To read the full article Peer-reviewed Article PDF image

Author(s): Sayantani Ghosh Saugat Dey


Pioglitazone, thiazolidinedione, body weight, Type- 2 Diabetes Mellitus, insulin, oral hypoglycemic agents

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version